AU3082401A - Therapy of psoriasis - Google Patents

Therapy of psoriasis

Info

Publication number
AU3082401A
AU3082401A AU30824/01A AU3082401A AU3082401A AU 3082401 A AU3082401 A AU 3082401A AU 30824/01 A AU30824/01 A AU 30824/01A AU 3082401 A AU3082401 A AU 3082401A AU 3082401 A AU3082401 A AU 3082401A
Authority
AU
Australia
Prior art keywords
psoriasis
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30824/01A
Inventor
David J. Shealy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of AU3082401A publication Critical patent/AU3082401A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU30824/01A 1999-11-24 2000-11-15 Therapy of psoriasis Abandoned AU3082401A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16747099P 1999-11-24 1999-11-24
US60167470 1999-11-24
PCT/US2000/042161 WO2001037874A2 (en) 1999-11-24 2000-11-15 Treatment of psoriasis by using an antibody to tnf alpha

Publications (1)

Publication Number Publication Date
AU3082401A true AU3082401A (en) 2001-06-04

Family

ID=22607484

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30824/01A Abandoned AU3082401A (en) 1999-11-24 2000-11-15 Therapy of psoriasis

Country Status (2)

Country Link
AU (1) AU3082401A (en)
WO (1) WO2001037874A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
EP2371859A3 (en) * 2002-07-19 2011-12-28 Abbott Biotechnology Ltd Treatment of TNF alpha related disorders
TWI556829B (en) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 Multiple-variable dose regimen for treating tnfα-related disorders
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
JP2023554200A (en) 2020-12-09 2023-12-26 エイチケー イノ．エヌ コーポレーション Anti-OX40L antibody, anti-OX40L and anti-TNFα bispecific antibody, and their uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015908D0 (en) * 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin

Also Published As

Publication number Publication date
WO2001037874A2 (en) 2001-05-31
WO2001037874A3 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
AU3867400A (en) Methods of using bioelastomers
AU3891299A (en) Combination therapy for treatment of depression
EP1176964B8 (en) Uses of et743 for treating cancer
AU7882900A (en) Hydrotherapy bed
AU3082401A (en) Therapy of psoriasis
AU1356201A (en) Treatment of hyperproliferative disorders
AU3896900A (en) Treatment of pain
AU7792900A (en) Distribution of certifiers
AU2451500A (en) Therapeutic agents
AU3760900A (en) Treatment of menstrual function
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
AU2001261324A1 (en) Psoriasis treatment
AU5973600A (en) Therapeutic agents
AU1405001A (en) Treatment of diseases
AU5646300A (en) Methods of stimulating angiogenesis
AU3064800A (en) The therapeutic use of r-warfarin as anticoagulant
AU1618901A (en) Treatment of rosacea
AU4598400A (en) Method of treatment
AU1037301A (en) Therapy of cephalic pain
AU2382601A (en) Novel method of treatment
AU6150200A (en) Therapeutic agents
AU4552700A (en) Gene therapy
AU5817400A (en) Therapeutic agents
AUPQ373899A0 (en) Treatment of asthma II

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase